The oncology innovation landscape has become increasingly competitive, with capital, strategic attention, and acquisition interest concentrated around companies that can show clear differentiation early. For emerging oncology companies, scientific novelty alone is no longer enough. Investors and potential buyers are looking for focused strategies, credible development paths, and a clear view of where a company can create value in a crowded market.
Â
J&J invites you to an event focused on how oncology startups can position themselves for investment, partnership, and potential acquisition in today’s market. The discussion will explore what different types of investors and acquirers are looking for, how expectations are evolving around patient selection and clinical trial design, and how companies can make strategic choices earlier in development that strengthen their future options.
Â
The program will also examine how buyer expectations differ across the oncology ecosystem. While large pharma may continue to prioritize broader opportunities with substantial commercial potential, mid-sized pharma and other strategic buyers may be more attracted to focused mechanisms of action, niche indications, strong unmet need, and clear development logic. Understanding these differences can help founders avoid being boxed in too early and build a strategy that fits both the science and the market.
Â
Join us in Utrecht or virtually for an open discussion with investors, pharma leaders, biotech executives, and advisors on what it takes to stand out in oncology today. The conversation will address changing market dynamics, competitive positioning, capital constraints, and the practical decisions that shape whether a company becomes investable, partnerable, or acquirable.
Â
The program is tailored to oncology startups, academic innovators, investors, TTOs, incubators, and ecosystem partners interested in how promising oncology science can be translated into companies that are strategically focused, commercially credible, and attractive to future partners or buyers.
- Janine Arts, Sr. Director Oncology External Innovation, Johnson & Johnson
- Mark Throsby, Drug developer and biotech entrepreneur
- Mark Panesar, Leerink Partners*
- VC representative
- Co-moderator: Nadiya Ishnazarova, Principal Venture Investments, Johnson & Johnson Innovation – JJDC
- Co-moderator: Cheryl Zimberlin, Managing Director, Ligase BioPartners
This program is from Johnson & Johnson and represents a selection of activities from across our Innovation Centers, JLABS and JJDC. The information in this program is for informational purposes only. The information is either proprietary or licensed to Johnson & Johnson and its affiliates or is provided by or proprietary to third parties. In case of third-party information, please note that only those third parties that provided or own this information are responsible for it. By providing this information, Johnson & Johnson do not endorse these third parties or any of the information provided in this program. This content is not intended to influence the use, sale, recommendation, or promotion of any products or services of Johnson & Johnson. Johnson & Johnson is not responsible or liable for any actions you do or do not take in relation to this information and are not responsible for any use of this information by you. By providing the information in this program, Johnson & Johnson does not make any representations, warranties, or assurances, express or implied, as to the content or the information presented in this program and is not responsible for any use by or alterations of this information by you. Johnson & Johnson hereby expressly disclaims any and all guarantees, representations, warranties, or assurances and assumes no responsibility or liability, direct or indirect in relation to the information in this program.